X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (228) 228
female (164) 164
male (160) 160
index medicus (159) 159
middle aged (157) 157
adult (154) 154
hematology (151) 151
aged (112) 112
prognosis (92) 92
treatment outcome (87) 87
adolescent (82) 82
oncology (79) 79
cancer (64) 64
life sciences (59) 59
chemotherapy (57) 57
young adult (57) 57
abridged index medicus (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (49) 49
leukemia, myeloid, acute - drug therapy (49) 49
disease-free survival (48) 48
leukemia, myeloid, acute - genetics (48) 48
survival rate (46) 46
acute myeloid leukemia (43) 43
aged, 80 and over (40) 40
therapy (39) 39
acute myeloid-leukemia (38) 38
mutation (38) 38
recurrence (38) 38
remission induction (38) 38
leukemia (37) 37
survival analysis (37) 37
retrospective studies (34) 34
acute myelogenous leukemia (33) 33
antineoplastic agents - therapeutic use (32) 32
leukemia, myeloid, acute - mortality (31) 31
aml (30) 30
minimal residual disease (30) 30
leukemia, myeloid, acute - diagnosis (29) 29
immunology (28) 28
child (26) 26
hemic and lymphatic diseases (26) 26
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (25) 25
follow-up studies (24) 24
risk factors (24) 24
survival (24) 24
time factors (24) 24
leukemia, myeloid, acute - therapy (22) 22
relapse (22) 22
trial (21) 21
[sdv.can]life sciences [q-bio]/cancer (20) 20
acute lymphoblastic-leukemia (20) 20
adults (20) 20
[ sdv.can ] life sciences [q-bio]/cancer (19) 19
cytarabine - administration & dosage (19) 19
mutations (19) 19
stem-cell transplantation (19) 19
trans-retinoic acid (19) 19
child, preschool (18) 18
drug administration schedule (18) 18
hematology, oncology and palliative medicine (18) 18
stem cell transplantation (18) 18
acute lymphoblastic leukemia (17) 17
antineoplastic agents - adverse effects (17) 17
care and treatment (17) 17
expression (17) 17
intensive chemotherapy (17) 17
leukemia, promyelocytic, acute - drug therapy (17) 17
prospective studies (17) 17
acute disease (16) 16
antineoplastic agents - administration & dosage (16) 16
children (16) 16
france (16) 16
neoplasm, residual (16) 16
acute promyelocytic leukemia (15) 15
daunorubicin - administration & dosage (15) 15
elderly-patients (15) 15
induction chemotherapy (15) 15
leukemia, myeloid, acute - pathology (15) 15
older patients (15) 15
philadelphia chromosome (15) 15
precursor t-cell lymphoblastic leukemia-lymphoma - genetics (15) 15
remission (15) 15
translocation, genetic (15) 15
acute lymphocytic-leukemia (14) 14
adult patients (14) 14
clinical trials (14) 14
cytogenetics (14) 14
diagnosis (14) 14
patients (14) 14
transplantation (14) 14
clinical trials as topic (13) 13
colony-stimulating factor (13) 13
drug resistance, neoplasm (13) 13
hematopoietic stem cell transplantation (13) 13
imatinib mesylate (13) 13
analysis (12) 12
antineoplastic combined chemotherapy protocols (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
arsenic trioxide (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
Blood, ISSN 0006-4971, 01/2016, Volume 127, Issue 1, pp. 53 - 61
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 22, pp. 4317 - 4323
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 57 - 66
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 9, pp. 836 - 847
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 02/2017, Volume 18, Issue 2, pp. 415 - 415
Journal Article